Full Press Release Details
ADVANCED - 2 TRIAL INTERIM RESULTS December 2024 FORWARD LOOKING STATEMENTS Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 . Protara may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "designed," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward - looking statements . Such forward - looking statements include but are not limited to, statements regarding Protara's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things : Protara's business strategy, including its development plans for its product candidates and plans regarding the timing or outcome of existing or future clinical trials (including reporting initial data from 12 - month evaluable patients in mid - 2025 ) ; statements related to expectations regarding interactions with the FDA , Protara's financial footing ; statements regarding the anticipated safety or efficacy of Protara's product candidates ; and Protara's outlook for the remainder of the year and future periods . Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward - looking statements . Factors that contribute to the uncertain nature of the forward - looking statements include : risks that Protara's financial guidance may not be as expected, as well as risks and uncertainties associated with : Protara's development programs, including the initiation and completion of non - clinical studies and clinical trials and the timing of required filings with the FDA and other regulatory agencies ; general market conditions ; changes in the competitive landscape ; changes in Protara's strategic and commercial plans ; Protara's ability to obtain sufficient financing to fund its strategic plans and development and commercialization efforts ; having to use cash in ways or on timing other than expected ; the impact of market volatility on cash reserves ; the loss of key members of management ; the impact of general U . S . and foreign, economic, industry, market, regulatory, political or public health conditions ; and the risks and uncertainties associated with Protara's business and financial condition in general, including the risks and uncertainties described more fully under the caption "Risk Factors" and elsewhere in Protara's filings and reports with the United States Securities and Exchange Commission . All forward - looking statements contained in this presentation speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date . Protara undertakes no obligation to update any forward - looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law . 2 2024 Protara Therapeutics. All Rights Reserved - Do Not Copy or Distribute Promising NMIBC therapy C de - risked rare disease programs 3 TARA - 002 in NMIBC Dosing underway in Phase 2 STARBORN - 1 trial TARA - 002 predecessor is standard of care in Japan U.S. FDA granted Rare Pediatric Disease Designation - PRV eligible Positive interim results from ADVANCED - 2 trial in NMIBC Unique product characteristics anticipated to drive significant adoption Potential to expand clinical program into BCG - na ve, combinations, systemic dosing and intermediate risk Oncology Rare Disease TARA - 002 in LMs 1. Data on file 2024 Protara Therapeutics. All Rights Reserved - Do Not Copy or Distribute IV Choline for Parenteral Support Enrolling pivotal study with PK endpoint 30K patient population